Showing papers in "Lung Cancer in 2007"

TL;DR: Results highlight younger age and specific physical and psychosocial symptoms as predictive of clinically significant distress as well as problems in the areas of family relationships, emotional functioning, and lack of information about diagnosis/treatment.

TL;DR: Data suggest that overexpression and strong binding of various DNMTs may result in promoter hypermethylation of multiple TSGs and ultimately lead to lung tumorigenesis and poor prognosis.

TL;DR: This pilot trial allows estimating that non-calcified nodules are 10 times more often detected from LDCT than from CXR, and speaks to the need for a high level of GPs formation and a large, coordinated clinical research team in such a trial.

TL;DR: It seems to be important to prevent SREs during the treatment of NSCLC, so further studies evaluating bisphosphonates in combination with chemotherapy are warranted.

TL;DR: Current data indicate that cyclin D1 overexpression is not a consequence of, but rather a pivotal element in the process of malignant transformation in the lung and other tissues, which may open new avenues for lung cancer diagnosis, treatment and prevention.

TL;DR: The results suggest that IL-8 increases cell proliferation in NSCLC cell lines via transactivation of the EGFR and that this mechanism involves metalloproteinase activity.

TL;DR: The pattern of increasing proportions of women with NSCLC and the increasing frequency of adenocarcinoma was substantiated, and treatment strategies depended more on stage and age than comorbid burden.

TL;DR: The hypothesis that tumor cell differentiation in combination with overexpression of GLUT-1 andGLUT-3 determine the extent of FDG accumulation and that squamous cell carcinomas accumulate more FDG than adenocarcinomas or large cell carcinoma is supported.

TL;DR: The data indicate that lung cancer screening may serve as a teachable moment for smoking cessation, and suggest that a smoking cessation trial within the context of lung cancer screenings is feasible.

TL;DR: Isolated nodal recurrence following PET-staged I NSCLC treated with SBRT is uncommon, and moderate post-SBRT PET hypermetabolic activity may persist 2 years following treatment without definite evidence of recurrence.

TL;DR: Gefitinib monotherapy leads to objective responses in most patients with EGFR mutations and small molecule TKIs are the new treatment paradigm for EGFR-mutant NSCLC.

TL;DR: In this article, a significant impact of PET-derived contours on treatment planning has been shown in 30-60% of the plans with respect to the CT-only target volume, with the most prominent changes in the gross tumour volume (GTV) reported in cases with atelectasis and following the incorporation of PETpositive nodes in otherwise CT-insignificant nodal areas.

TL;DR: Respiratory Function and exercise capacity significantly improve following a post-operative 4-week i-PR in lung resected patients and could be regarded as a component of the management of patients who have undergone LR for cancer.

TL;DR: Gefitinib has promising activity in palliative therapy for patients with advanced lung adenocarcinoma and brain metastasis, and was well-tolerated, with cutaneous reactions as the most frequent toxicity.

TL;DR: In MPM, the combined modality approach using the Carboplatin/Gemcitabine combination as induction chemotherapy is feasible, with good results in terms of survival and morbidity.

TL;DR: The joint analysis of array CGH and gene expression analysis highlights genes with concordant changes in expression and copy number that may be critical to lung cancer development and progression.

TL;DR: QoL evolution profiles comparing pre-operative status with deficits and changes at 1, 3, 6 and 12 months after pulmonary surgery are documented.

TL;DR: Analysis of tumor EGFR mutations in patients with NSCLC could be used to identify patients suitable for treatment with gefitinib to obtain optimum response and disease control rates.

TL;DR: Advanced pulmonary pleomorphic carcinoma showed poor response to chemotherapy regimens that provide active treatment for NSCLC, and novel treatment approaches are required for pulmonary pleomorph carcinoma.

TL;DR: It is suggested that inhibition of Sirt1 by ASODN may be a potential gene therapy approach to the treatment of lung cancer and decreases survival and increases radiation-induced antiproliferation effects of human lung cancer cells.

TL;DR: A female sex and a spiculated mGGO border were found to be related with malignancy, suggesting that pulmonary infiltrate with eosinophilia (PIE) might have been responsible, and short-term follow-up by chest HRCT be conducted for m GGO lesions in the presence of high eos inophilia--regardless of lesion size.

TL;DR: Low-dose CT screening substantially improves the 10-year survival for lung cancer with minimal use of invasive treatment procedures and a poorer prognosis was noted in smokers with adenocarcinomas/mixed types, associated with part-solid or solid CT density pattern and Noguchi's type C or D.

TL;DR: The patients with all stages of disease who had positive RASSF1A, RUNX3, or H-cadherin methylation status were found to have a significantly shorter duration of survival, as compared with the patients with a negativemethylation status for those genes, and the hypermethylation of RASSf1A or RunX3 gene is therefore a useful biomarker to predict the prognosis in NSCLC.

TL;DR: The results indicate that the expression of HLA-G is a characteristic feature of NSCLC, and they suggest that immunostaining by anti-HLA-G antibodies may be a potentially useful prognostic indicator.

TL;DR: It is proposed, in agreement with earlier findings for prostate-, breast- colon cancer and Hodgkins lymphoma, that a high level of sun-induced 25-hydroxyvitamin D can be a prognostic advantage for certain groups of lung cancer patients, notably for young men.

TL;DR: The overexpression of MMP-7 was associated with tumor proliferation, and a poor prognosis in NSCLCs, and Wnt1 may play a critical role in regulating the intratumoral M MP-7 expression.

TL;DR: A retrospective review of patients with primary non-small cell lung cancer treated in a monocentric institution between 1996 and 2005 found gender and histology to be independent significant prognostic factors for survival.

TL;DR: In a case of small cell lung cancer developing after prolonged treatment for primary adenocarcinoma of the lung, it is suggested that the activating EGFR mutations may confer the pathogenesis of a subset of SCLC.

TL;DR: V vessel invasion is a poor prognostic factor in patients with stage IA NSCLC and is improved significantly by postoperative oral uracil-tegafur chemotherapy, a preliminary study suggests.